HSBC Holdings’s Cymabay Therapeutics CBAY Stock Holding History

HSBC Holdings’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-24,763	Closed	-$127K	–	3228
2019 Q3	$127K	Buy	+24,763	New	+$150K	﹤0.01%	2952

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HSBC Holdings's CBAY Position: Q4 2019 in Review

HSBC Holdings sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 24,763 shares — an estimated $127K sold.

HSBC Holdings first reported a position in CBAY in Q3 2019 and held it in 1 quarter. The position peaked at $127K in Q3 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

HSBC Holdings reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
HSBC Holdings sold 24,763 Cymabay Therapeutics shares in Q4 2019, an estimated $127K.
HSBC Holdings first reported a position in Cymabay Therapeutics in Q3 2019 and held it in 1 quarter.
HSBC Holdings's Cymabay Therapeutics position peaked at $127K in Q3 2019.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on HSBC Holdings's 13F filing for Q4 2019, filed 14 Feb 2020.